<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00350129</url>
  </required_header>
  <id_info>
    <org_study_id>005-ZAC-2004-002</org_study_id>
    <nct_id>NCT00350129</nct_id>
  </id_info>
  <brief_title>Effect of Glucose on Ocular Blood Flow</brief_title>
  <official_title>Influence of Plasma Glucose Levels on Retinal Vascular Diameter and Choroidal Blood Flow in Vasospastic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess the effect of glucose on retinal vascular diameter in&#xD;
      otherwise healthy vasospastic subjects compared to non-vasospastic controls.&#xD;
&#xD;
      The secondary objective is to compare the effect of glucose also on choroidal blood flow in&#xD;
      otherwise healthy vasospastic subjects with non-vasospastic controls.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is known that a glucose load can induce an increase in ocular blood flow. Acute&#xD;
      hyperglycemia increases retinal vessel diameters in animals and humans. The purpose of this&#xD;
      study is to compare the effect of glucose on the ocular blood flow in vasospastics and&#xD;
      nonvasospastics. Body core temperature depends on basal metabolism. Peripheral&#xD;
      vasoconstriction is a physiological way to preserve core temperature of the body. The&#xD;
      etiology of primary vasospastic syndrome is unknown and potentially represents simply a&#xD;
      reaction to a defective metabolism. Based on this hypothesis, vasospastics are expected to&#xD;
      show a different vascular reaction to glucose.&#xD;
&#xD;
      On both study days, after an overnight fast, the subjects will be seated for 30 minutes in&#xD;
      the Lab and local tropicamide will be applied for pupil dilatation. After stabilisation of&#xD;
      blood pressure Retinal vessel diameter and choroidal blood flow will be assessed. Baseline&#xD;
      blood glucose levels will be measured. Afterwards study substance (75 gram of Glucose or&#xD;
      Aspartate) will be applied in 3 dl of water. One and a half hour later, the vascular&#xD;
      measurements will be repeated. Ath the end of hemodynamic assessments, blood sugar level will&#xD;
      be measured again.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">February 2003</completion_date>
  <primary_completion_date type="Actual">February 2003</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">24</enrollment>
  <condition>Coronary Vasospasm</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>healthy vasospastic subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>healthy non-vasospastic subjects</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        healthy vasospastic subjects, healthy non-vasospastic subjects&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  No history of the following problems: ocular or systemic disease; chronic or current&#xD;
             systemic or topical medication; or of drug or alcohol abuse&#xD;
&#xD;
          -  normal blood pressure (100-140 / 60-90 mmhg)&#xD;
&#xD;
          -  best corrected visual acuity above 20/25 in both eyes&#xD;
&#xD;
          -  no pathological findings upon a slit-lamp examination and indirect fundoscopy&#xD;
&#xD;
          -  ametropia within -3 to +3 diopters of spherical equivalent&#xD;
&#xD;
          -  less than 1 diopter astigmatism&#xD;
&#xD;
          -  IOP &lt; 20 mmHg in both eyes&#xD;
&#xD;
          -  Subjects will be classified as vasospastic if they relate a clear history of frequent&#xD;
             cold hands (answering yes to the questions: &quot;do you have always cold hands, even&#xD;
             during summer time?&quot; and &quot;do other people tell you that you have cold hands?&quot;) and as&#xD;
             normals if they deny such a history&#xD;
&#xD;
          -  Vasospastic propensity will also be assessed by capillaroscopy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects describing &quot;sometimes cold hands&quot;&#xD;
&#xD;
          -  if the test substance cannot be ingested&#xD;
&#xD;
          -  not obtainable ocular blood flow measurements&#xD;
&#xD;
          -  abnormally high levels of glucose at any point in time&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Selim Org√ºl, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Basel, Eye Clinic</name>
      <address>
        <city>Basel</city>
        <state>BS</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <study_first_submitted>July 7, 2006</study_first_submitted>
  <study_first_submitted_qc>July 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2006</study_first_posted>
  <last_update_submitted>September 25, 2008</last_update_submitted>
  <last_update_submitted_qc>September 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2008</last_update_posted>
  <responsible_party>
    <name_title>Selim Orgul</name_title>
    <organization>University Hospital, Basel, Switzerland</organization>
  </responsible_party>
  <keyword>glucose</keyword>
  <keyword>vasospasm</keyword>
  <keyword>RVA</keyword>
  <keyword>LDF</keyword>
  <keyword>vasospastic subjects</keyword>
  <keyword>non-vasospastic subjects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Vasospasm</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

